Avid Radiopharmaceuticals
Adam Hoye is a seasoned professional in the field of chemistry, currently serving as Senior Director of Chemistry at Eli Lilly and Company since October 2022. Prior to this role, Adam Hoye held various positions at Avid Radiopharmaceuticals, including Senior Research Chemist, Research Advisor, Principal Research Scientist, and Research Chemist, beginning in October 2012. Adam Hoye also gained valuable experience as a Postdoctoral Associate at the University of Pennsylvania from October 2010 to October 2012. Adam Hoye earned a Doctor of Philosophy (Ph.D.) in Organic Chemistry from the University of Pittsburgh in 2010 and a Bachelor of Arts (B.A.) in Chemistry from Grinnell College in 2004.
Avid Radiopharmaceuticals
1 followers
At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.